Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
UCSF Neuroimmunology Seminar
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Receptos reports third quarter 2013 financial results
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Pages